Rob Dillard

DocwireNews

The Janssen Pharmaceutical Companies of Johnson &amp; Johnson recently announced that the U.S. Food and Drug Administration (FDA) has proved two pediatric indications for XARELTO® (rivaroxaban) for the treatment of venous thromboembolism (VTE)in patients from birth to less than 18 years after at least five days of parenteral anticoagulant treatment.
XARELTO® stands as the only direct oral anticoagulant (DOAC) FDA-approved for the primary prevention of clots in pediatric patients following the Fontan procedure and the only U.S. treatment to offer an oral suspension formulation.
According to the company, the oral suspension formulation will be administered through a color-coded dosing device developed to help minimize dosing errors. The device is expected and is expected to become available in the U.S. for pediatric patients in mid-January of this year. The oral tablets are currently available in the U.S. for appropriate pediatric patients.
“Historically, there has been limited guidance and options for healthcare providers on how to help reduce potentially serious, even fatal, blood clots and related events in young children,” said Andrew Van Bergen, M.D., Pediatric Cardiologist, Advocate Children’s Hospital via a <a href="https://www.prnewswire.com/news-releases/fda-approves-two-new-indications-for-xarelto-rivaroxaban-to-help-prevent-and-treat-blood-clots-in-pediatric-patients-301448701.html?tc=eml_cleartime">press release</a>. * “We have had to adjust adult doses of standard anticoagulation therapies, which are both burdensome and uncomfortable for patients, and require frequent monitoring. Now that XARELTO® is FDA-approved with weight-based dosing options, either as tablets or liquid formulation, a convenient option is available allowing flexibility to tailor the treatment for my patients. This is a major advancement in antithrombotic care for those patients under the age of 18.”
“When a child is experiencing health challenges, learning that they are also at risk for a blood clot can feel overwhelming for the patient, and also their parents or caregivers,” said Andrea Baer, MS, BCPA, Executive Director of The Mended Hearts, Inc., a patient advocacy organization whose program Mended Little Hearts serves patients and families with congenital heart disease.** “Knowing that there is now an FDA-approved oral treatment option to reduce the risk of blood clots that’s easy and may be more comfortable than injections to administer may help ease that burden.”

The Janssen Pharmaceutical Companies of Johnson &amp; Johnson recently announced that the U.S. Food and Drug Administration (FDA) has proved two pediatric indications for XARELTO® (rivaroxaban) for the treatment of venous thromboembolism (VTE)in patients from birth to less than 18 years after at least five days of parenteral anticoagulant treatment.XARELTO® stands as the only direct oral anticoagulant (DOAC) FDA-approved for the primary prevention of clots in pediatric patients following the Fontan procedure and the only U.S. treatment to offer an oral suspension formulation.According to the company, the oral suspension formulation will be administered through a color-coded dosing device developed to help minimize dosing errors. The device is expected and is expected to become available in the U.S. for pediatric patients in mid-January of this year. The oral tablets are currently available in the U.S. for appropriate pediatric patients.“Historically, there has been limited guidance and options for healthcare providers on how to help reduce potentially serious, even fatal, blood clots and related events in young children,” said Andrew Van Bergen, M.D., Pediatric Cardiologist, Advocate Children’s Hospital via a <a href="https://www.prnewswire.com/news-releases/fda-approves-two-new-indications-for-xarelto-rivaroxaban-to-help-prevent-and-treat-blood-clots-in-pediatric-patients-301448701.html?tc=eml_cleartime">press release</a>. * “We have had to adjust adult doses of standard anticoagulation therapies, which are both burdensome and uncomfortable for patients, and require frequent monitoring. Now that XARELTO® is FDA-approved with weight-based dosing options, either as tablets or liquid formulation, a convenient option is available allowing flexibility to tailor the treatment for my patients. This is a major advancement in antithrombotic care for those patients under the age of 18.”“When a child is experiencing health challenges, learning that they are also at risk for a blood clot can feel overwhelming for the patient, and also their parents or caregivers,” said Andrea Baer, MS, BCPA, Executive Director of The Mended Hearts, Inc., a patient advocacy organization whose program Mended Little Hearts serves patients and families with congenital heart disease.** “Knowing that there is now an FDA-approved oral treatment option to reduce the risk of blood clots that’s easy and may be more comfortable than injections to administer may help ease that burden.”

Lauren Dembeck, PhD

Two Decades of IBS Tweets Offer Insight Into Patient Experience and Care Priorities

Leah Lawrence

FIT Identifies Premalignant and Malignant Colorectal Polyps

Colon Polyps

Mark E. Robson, MD

Optimizing PARP Inhibitor Use in TNBC: Mechanisms, Combinations, and Clinical Strategies

Triple-Negative Breast Cancer

Latest News

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat VTE in Pediatric Patients

The Janssen Pharmaceutical Companies of Johnson &amp; Johnson recently announced that the U.S. Food and Drug Administration (FDA) has proved two pediatric indications for ...

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat VTE in

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Diabetes

Obesity

Metabolic Care Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe